Evinacumab

Phase 3

Regeneron Pharmaceuticals, Inc. (REGN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Hypercholesterolemia

SNYPlacebo (for Alirocumab)

Phase 3

View Full Landscape

Drug Information

Target Indication

Hypercholesterolemia

Clinical Trial

NCT03175367

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/17/2021

Evkeeza

Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AlirocumabPhase 3

Homozygous Familial Hypercholesterolemia

StatinPhase 3

Hypercholesterolemia

Intravitreal Aflibercept Injection (IAI)Phase 3

Neovascular Age-Related Macular Degeneration

LibtayoPhase 3

Non-Small Cell Lung Cancer

REGN5715Phase 3

Allergic Conjunctivitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts